The incidence of advanced stage cancer in the high relaxin-2 mRNA expression group (12 of 16, 75%) was significantly higher (P = 0.018) than that in the low relaxin-2 expression group (9 of 20, 45%), and the incidence of hematogenous metastasis in the high relaxin-2 mRNA expression group (17 of 21, 81%) was significantly higher (P = 0.002) than that in the low relaxin-2 expression group (4 of 25, 16%). Here, RLN2 is linked to cancer.